Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
112.59
+5.02 (4.67%)
Jul 30, 2026, 4:00 PM EDT - Market closed
Mirum Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 324.91 | 296.68 | 222.5 | 286.33 | 28 | 31.34 |
Short-Term Investments | 61.35 | 86.64 | 57.81 | - | 123.72 | 125.2 |
Cash & Short-Term Investments | 386.26 | 383.33 | 280.32 | 286.33 | 151.72 | 156.54 |
Cash Growth | 39.11% | 36.75% | -2.10% | 88.72% | -3.08% | -32.47% |
Accounts Receivable | 133.11 | 123.33 | 78.29 | 67.97 | 23.99 | 3.27 |
Inventory | 25.52 | 24.89 | 22.4 | 22.31 | 5.57 | 1.51 |
Other Current Assets | 24.55 | 18.14 | 11.78 | 10.94 | 8.95 | 5.27 |
Total Current Assets | 569.44 | 549.68 | 392.79 | 387.54 | 190.23 | 166.59 |
Net Property, Plant & Equipment | 15.06 | 10.6 | 9.81 | 1.99 | 60.39 | 2.55 |
Other Intangible Assets | 254.15 | 260.92 | 249.82 | 252.93 | 1.38 | 18.74 |
Long-Term Investments | 34.35 | 8.11 | 12.53 | - | - | 4.98 |
Other Long-Term Assets | 17.91 | 13.5 | 5.81 | 4.17 | 0.91 | 101.79 |
Total Assets | 890.92 | 842.81 | 670.75 | 646.62 | 352.91 | 294.65 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 59.4 | 9.61 | 14.62 | 7.42 | 8.69 | 9.17 |
Accrued Expenses | 187.63 | 196.19 | 111.93 | 78.54 | 54.02 | 30.72 |
Current Portion of Leases | - | - | - | 1.1 | 0.93 | 0.71 |
Other Current Liabilities | 25.8 | - | - | - | 1.09 | 2 |
Total Current Liabilities | 272.82 | 205.8 | 126.55 | 87.06 | 64.73 | 42.6 |
Long-Term Debt | 310.25 | 309.8 | 308.08 | 306.42 | - | - |
Long-Term Leases | 11.18 | 7.52 | 7.97 | 0.62 | 1.26 | 1.9 |
Other Long-Term Liabilities | 54.17 | 5.01 | 2.51 | 3.85 | 144.88 | 129.94 |
Total Long-Term Liabilities | 375.6 | 322.32 | 318.56 | 310.89 | 146.14 | 131.84 |
Total Liabilities | 648.42 | 528.12 | 445.11 | 397.95 | 210.87 | 174.44 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0 |
Additional Paid-in Capital | 1,700 | 981.88 | 870.19 | 803.26 | 535.07 | 377.4 |
Accumulated Other Comprehensive Income | -0.03 | 0.35 | -0.37 | 1.64 | -0.22 | -0.04 |
Retained Earnings | -1,458 | -667.54 | -644.18 | -556.24 | -392.82 | -257.16 |
Shareholders' Equity | 242.49 | 314.69 | 225.64 | 248.67 | 142.04 | 120.21 |
Total Liabilities & Equity | 890.92 | 842.81 | 670.75 | 646.62 | 352.91 | 294.65 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 321.43 | 317.31 | 316.05 | 308.14 | 2.19 | 2.61 |
Net Cash (Debt) | 64.83 | 66.01 | -35.74 | -21.82 | 149.53 | 153.93 |
Net Cash Growth | - | - | - | - | -2.86% | -32.65% |
Net Cash Per Share | 1.20 | 1.31 | -0.75 | -0.53 | 4.40 | 5.08 |
Book Value | 242.49 | 314.69 | 225.64 | 248.67 | 142.04 | 120.21 |
Book Value Per Share | 4.47 | 6.27 | 4.75 | 6.08 | 4.18 | 3.96 |
Tangible Book Value | -11.66 | 53.77 | -24.18 | -4.26 | 140.66 | 101.47 |
Tangible Book Value Per Share | -0.21 | 1.07 | -0.51 | -0.10 | 4.14 | 3.35 |